Targeting the root causes of biliary disease to change outcomes for patients
Learn MoreWe are a biotechnology company developing disease-modifying therapies for Primary Sclerosing Cholangitis (PSC), a rare and devastating liver disease with no approved treatments.
Based in Cambridge, Massachusetts, Daedalus Therapeutics operates as a resident company at LabCentral within the Kendall Square life sciences ecosystem.
Our long-term goal is to develop treatments that meaningfully alter the course of PSC — slowing or preventing progression to cirrhosis, reducing the risk of liver failure and malignancy, and improving outcomes for patients who currently have few options.
Zero approved disease-modifying therapies for PSC
Liver transplantation remains the only life-extending intervention
Young to middle-aged adults facing a lifelong progressive disease
Primary Sclerosing Cholangitis (PSC) is a rare, progressive cholestatic liver disease characterized by chronic inflammation and fibrosis of the bile ducts. The disease most often affects young to middle-aged adults and is strongly associated with inflammatory bowel disease.
PSC follows an unpredictable but relentlessly progressive course. Over time, ongoing bile duct injury leads to biliary stricturing, cholestasis, secondary hepatic fibrosis, cirrhosis, portal hypertension, and ultimately liver failure. Patients with PSC also face a markedly elevated lifetime risk of cholangiocarcinoma.
Despite decades of investigation, there are currently no approved disease-modifying therapies for PSC. Prior therapeutic efforts have largely focused on bile acid composition, symptomatic endpoints, or downstream inflammatory markers, with limited evidence of durable impact on disease progression.
A central challenge in PSC drug development has been the complexity of bile duct–centered pathology and the lack of translational models that directly connect molecular mechanisms to epithelial injury and fibrotic progression.